Course Detail

Best of ACTHIV® 2023: Initial ART Regimens for the Newly Diagnosed Patient with HIV

Details

Published Date: 09/15/2023

Expiration Date: 09/15/2024

CE Credit: CME:0.5

Description

Selected by attendees and the program planning committee as one of the best sessions of the ACTHIV® 2023 conference for the frontline HIV care team, this module reviews first-line HIV regimens for newly-diagnosed patients with HIV including side effects, discusses rapid ART initiation in newly-diagnosed patients, explores adherence challenges on oral ART and use of long-acting ART, and provides guidance on initial ART if seroconversion occurs on long-acting PrEP.

Presenter(s)

Monica Gandhi,MD, MPH

Monica Gandhi MD, MPH, is a Professor of Medicine and Associate Chief in the Division of HIV, Infectious Diseases, and Global Medicine at the University of California, San Francisco (UCSF). She is also the Director of the UCSF Center for AIDS Research (CFAR) and the Medical Director of the HIV Clinic ("Ward 86") at San Francisco General Hospital. Her research focuses on HIV treatment and prevention optimization, HIV and women, adherence measurement in HIV and TB, adherence interventions, and the interplay between COVID-19 and HIV. She recently worked on COVID-19 mitigation and vaccination strategies, with a book on the COVID-19 pandemic (called “Endemic: A Post Pandemic Playbook”) coming out from Mayo Clinic Press in 2023.

Learning Objectives

Review first-line HIV regimens for newly-diagnosed patients with HIV including side effects.
Discuss rapid ART initiation in newly-diagnosed patients
Explore adherence challenges on oral ART and use of long-acting ART.
Apply guidance on initial ART if seroconversion occurs on long-acting PrEP.

Continuing Education Credit Information

Learn more and Enroll